Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer

Histopathology

Volumn 57, Issue 6, 2010, Pages 885-892

  Morikawa, Teppei ^a   Maeda, Daichi ^a   Kume, Haruki ^b   Homma, Yukio ^b   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bladder cancer; Gemcitabine; Immunohistochemistry; Ribonucleotide reductase M2 subunit; Urothelial carcinoma

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER CELL; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTECTOMY; CYSTITIS; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING; TISSUE MICROARRAY; UROTHELIAL CARCINOMA; UROTHELIUM; UROTHELIUM SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 78650253325     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03725.x     Document Type: Article

References (26)

1. Parkin DM. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. 2008; 218; 12-20.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58; 71-96.
3. Rubben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 1988; 139; 283-285.
4. Addeo R, Caraglia M, Bellini S et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol. 2010; 28; 543-548.
5. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000; 18; 3068-3077.
6. Thelander M, Graslund A, Thelander L. Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2- overproducing mouse cells. J. Biol. Chem. 1985; 260; 2737-2741.
7. Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 2009; 41; 77-88.
8. Eriksson S, Martin DW Jr. Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle- dependent variation in the activity of subunit protein M2. J. Biol. Chem. 1981; 256; 9436-9440.
9. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23; 1539-1548.
10. Itoi T, Sofuni A, Fukushima N et al. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J. Gastroenterol. 2007; 42; 389-394.
11. Duxbury MS, Whang EE. RRM2 induces NF- kappaB- dependent MMP- 9 activation and enhances cellular invasiveness. Biochem. Biophys. Res. Commun. 2007; 354; 190-196.
12. Zhang K, Hu S, Wu J et al. Overexpression of RRM2 decreases thrombspondin- 1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol. Cancer 2009; 8; 11.
13. Liu X, Zhou B, Xue L et al. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin. Colorectal Cancer 2007; 6; 374-381.
14. Souglakos J, Boukovinas I, Taron M et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br. J. Cancer 2008; 98; 1710-1715.
15. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch. 2002; 441; 105-108.
16. Greene FL, Page DL, Fleming ID et al. AJCC cancer staging manual, 6th edn. Philadelphia, PA: Lippincott- Raven, 2002; 335-337.
17. Ito H, Funahashi S, Yamauchi N et al. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin. Cancer Res. 2006; 12; 3257-3264.
18. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non- neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am. J. Surg. Pathol. 2001; 25; 1074-1078.
19. Mansy SS. Agarose cell block: innovated technique for the processing of urine cytology for electron microscopy examination. Ultrastruct. Pathol. 2004; 28; 15-21.
20. Morikawa T, Sugiyama A, Kume H et al. Identification of Toll- like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin. Cancer Res. 2007; 13; 5703-5709.
21. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki- 67 as objective markers of urothelial dysplasia. Mod. Pathol. 2003; 16; 187-191.
22. Kolesar J, Huang W, Eickhoff J et al. Evaluation of mRNA by Q- RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother. Pharmacol. 2009; 64; 79-86.
23. Yun HJ, Cho YH, Moon Y et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp. Mol. Med. 2008; 40; 345-353.
24. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ. Overview of ribonucleotide reductase inhibitors: an appealing target in anti- tumour therapy. Curr. Med. Chem. 2005; 12; 1283-1294.
25. Shibata SI, Doroshow JH, Frankel P et al. Phase I trial of GTI- 2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother. Pharmacol. 2009; 64; 1149-1155.
26. Nogawa M, Yuasa T, Kimura S et al. Intravesical administration of small interfering RNA targeting PLK- 1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 2005; 115; 978-985.